Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of lutetium Lu 177 dotatate with carboplatin, etoposide, and atezolizumab in newly diagnosed extensive-stage small cell lung cancer
CTR20252063Phase 2Active
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in small cell lung cancer (SCLC), sponsored by Novartis. Started Sep 2025; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20252063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252063.